RA
Rosalind Advisors Portfolio holdings
AUM
$207M
This Quarter Return
-3.21%
1 Year Return
+62.29%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$126M
AUM Growth
+$126M
(+18%)
Cap. Flow
+$29.9M
Cap. Flow
% of AUM
23.67%
Top 10 Holdings %
Top 10 Hldgs %
61.47%
Holding
43
New
5
Increased
13
Reduced
5
Closed
1
Top Buys
| 1 |
Delcath Systems
DCTH
|
$9.44M |
| 2 |
Abeona Therapeutics
ABEO
|
$7.42M |
| 3 |
Cellectar Biosciences
CLRB
|
$5.21M |
| 4 |
Ocular Therapeutix
OCUL
|
$5.13M |
| 5 |
InspireMD
NSPR
|
$4.56M |
Top Sells
| 1 |
Kiora Pharmaceuticals
KPRX
|
$8.59M |
| 2 |
Veru
VERU
|
$1.52M |
| 3 |
TVRD
Tvardi Therapeutics, Inc. Common Stock
TVRD
|
$1.41M |
| 4 |
Tonix Pharmaceuticals
TNXP
|
$609K |
| 5 |
Unicycive Therapeutics
UNCY
|
$155K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Delcath Systems
DCTH
$385M
| $15.5M | 11.95% | 2,650,389 +1,611,561 | +155% | +$9.44M |
|
2
Myomo
MYO
$39.7M
| $8.55M | 6.58% | 2,664,999 +217,259 | +9% | +$697K |
|
3
MediWound
MDWD
$182M
| $7.97M | 6.13% | 513,490 +27,500 | +6% | +$427K |
|
|
OPTN
4
DELISTED
OptiNose
OPTN
| $7.85M | 6.04% | 7,547,148 +3,005,659 | +66% | +$3.13M |
|
|
5
Abeona Therapeutics
ABEO
$350M
| $7.42M | 5.71% | +1,750,000 | New | +$7.42M |
|
6
Xeris Biopharma Holdings
XERS
$1.26B
| $7.02M | 5.4% | 3,120,170 +300,000 | +11% | +$675K |
|
|
7
Cellectar Biosciences
CLRB
$15.5M
| $6.76M | 5.21% | 2,705,616 +2,084,138 | +335% | +$5.21M |
|
|
8
InspireMD
NSPR
$102M
| $6.27M | 4.83% | 2,513,641 +1,827,579 | +266% | +$4.56M |
|
|
CYBN
9
Cybin
CYBN
$176M
| $5.23M | 4.02% | 19,300,000 +5,340,000 | +38% | +$1.45M |
|
|
10
Ocular Therapeutix
OCUL
$2.12B
| $5.13M | 3.95% | +750,000 | New | +$5.13M |
|
|
ABVX
11
Abivax
ABVX
$6.12B
| $5M | 3.85% | 378,416 | – | – |
|
|
PROF
12
Profound Medical
PROF
$134M
| $4.47M | 3.44% | 533,333 | – | – |
|
|
CMPS
13
Compass Pathways
CMPS
$424M
| $4.43M | 3.41% | 734,000 | – | – |
|
14
Trevi Therapeutics
TRVI
$883M
| $4.15M | 3.19% | 1,391,577 +465,561 | +50% | +$1.39M |
|
15
KalVista Pharmaceuticals
KALV
$678M
| $3.98M | 3.06% | 337,985 +50,000 | +17% | +$589K |
|
16
Viridian Therapeutics
VRDN
$1.5B
| $3.9M | 3% | 300,000 | – | – |
|
|
VRNA
17
Verona Pharma
VRNA
$9.16B
| $3.62M | 2.78% | 250,000 | – | – |
|
18
Clearside Biomedical
CLSD
$28.9M
| $3.37M | 2.59% | 2,592,593 | – | – |
|
19
Outlook Therapeutics
OTLK
$37.8M
| $3.32M | 2.56% | 450,000 +138,225 | +44% | +$1.02M |
|
|
20
Veru
VERU
$47.6M
| $2.27M | 1.75% | 2,696,003 -1,803,997 | -40% | -$1.52M |
|
21
PolyPid
PYPD
$53.3M
| $1.79M | 1.38% | 416,800 +1,000 | +0.2% | +$4.3K |
|
22
Rezolute
RZLT
$619M
| $1.08M | 0.83% | 250,000 +50,000 | +25% | +$215K |
|
|
23
Kiora Pharmaceuticals
KPRX
$9.55M
| $1.07M | 0.83% | 255,555 -2,044,445 | -89% | -$8.59M |
|
24
Fortress Biotech
FBIO
$76.8M
| $1.04M | 0.8% | 607,797 | – | – |
|
25
Geron
GERN
$893M
| $848K | 0.65% | 200,000 | – | – |
|